---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-273228"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:30:34.181606+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Olema Q3 net loss $42.2M; cash $329M; initiates OPERA-02 Phase 3; Pfizer deal

## Summary
- Net loss $42.2M for Q3 2025 vs $34.6M Q3 2024; cash, equivalents and securities $329.0M.
- Initiated OPERA-02 Phase 3 trial of palazestrant + ribociclib in frontline ER+/HER2- MBC.
- Clinical trial agreement with Pfizer to evaluate palazestrant + atirmociclib in Phase 1b/2.
- Phase 1/2 of OP-3136 (KAT6 inhibitor) expanded into combos; initial results expected mid-2026.
- Top-line data from OPERA-01 monotherapy Phase 3 expected in second half of 2026.

## SEC filing metadata
- accession: 0001193125-25-273228
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000119312525273228/0001193125-25-273228-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000119312525273228/olma-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-273228
- JSON: https://secwatch.observer/filing/0001193125-25-273228.json
- Plain text: https://secwatch.observer/filing/0001193125-25-273228.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.